Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States

Cytarabine-anthracycline based intensive induction chemotherapy (IC) remains the standard of care for remission induction among fit patients with newly diagnosed acute myeloid leukemia (AML) in the United States (US). However, the mortality rate outside of clinical IC trials, predictors of death, an...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Zeidan, Amer M., Podoltsev, Nikolai A., Wang, Xiaoyi, Zhang, Chi, Bewersdorf, Jan Philipp, Shallis, Rory M., Huntington, Scott F., Neparidze, Natalia, Giri, Smith, Gore, Steven D., Davidoff, Amy J., Ma, Xiaomei, Wang, Rong
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2020
Soggetti:
Myeloid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7189301/
https://ncbi.nlm.nih.gov/pubmed/32311013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001728
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi